The therapeutic promises of NAD<sup>+</sup> boosters.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34233170.
- Also identified by DOI 10.1016/j.cmet.2021.06.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Numerous preclinical studies implicate the decline in NAD+ signaling in developing aging- and obesity-associated metabolic disorders. Yoshino et al. (2021) now provide the clinical evidence that an NAD+ booster increases muscle insulin sensitivity in postmenopausal prediabetic women, validating the therapeutic promises of NAD+ boosters in humans.
Medical subject headings
- Insulin Resistance
- Prediabetic State